<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03790358</url>
  </required_header>
  <id_info>
    <org_study_id>15-1311</org_study_id>
    <nct_id>NCT03790358</nct_id>
  </id_info>
  <brief_title>Mood Effects of Serotonin Agonists</brief_title>
  <official_title>Mood Effects of Serotonin Agonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of very low doses of serotonergic
      agonists on depressed mood in human volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Profile of Mood States (POMS)</measure>
    <time_frame>End of study (Baseline - time 0 and approximately 8 weeks later)</time_frame>
    <description>The POMS measures individuals' mood states. This is a validated scale to measure positive and negative mood states. The POMS contains 30 items and assesses six identified mood factors: Tension-Anxiety, Depression-Ejection, Anger- Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment. Scoring of the instrument provides a global score of 0 to 120 or individual domain scores. Lower scores indicate better mood state. The POMS brief form is a simple self-rating instrument.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose MDMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6.5ug dose of serotonin agonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13ug dose of serotonin agonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>26ug dose of serotonin agonist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lysergic Acid Diethylamide</intervention_name>
    <description>Drug will be administered in solution form.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_label>low dose MDMA</arm_group_label>
    <arm_group_label>medium dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English fluency

          -  High school level education

          -  BMI between 19 and 30

        Exclusion Criteria:

          -  Diagnosed medical condition

          -  women who are nursing, pregnant, or plan to become pregnant within 3 months

          -  History of psychotic disorder or family history of psychotic disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Matthew Bona</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Bona</last_name>
      <phone>773-702-3560</phone>
      <email>mbona@yoda.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anya Bershad</last_name>
      <email>abershad@uchicago.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Bona</last_name>
      <phone>773-702-3560</phone>
      <email>mbona@yoda.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anya Bershad</last_name>
      <phone>773-702-7611</phone>
      <email>abershad@uchicago.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 21, 2018</study_first_submitted>
  <study_first_submitted_qc>December 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2018</study_first_posted>
  <last_update_submitted>December 28, 2018</last_update_submitted>
  <last_update_submitted_qc>December 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lysergic Acid Diethylamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

